A critical appraisal of the immunohistochemical detection of the c-myc oncogene product in colorectal cancer.
Affiliation
Department of Immunology, Paterson Institute for Cancer Research, Manchester, UK.Issue Date
1987-12
Metadata
Show full item recordAbstract
Expression of c-myc was studied immunohistochemically in 100 colorectal carcinomas, using a monoclonal antibody, Myc 1-6E10, which is purported to recognize the oncoprotein (p62c-myc) in paraffin-embedded material. In normal epithelium, maturing crypt cells and terminally differentiated surface cells were positive, and proliferating basal crypt cells negative. All carcinomas stained positively, but intensity was independent of histological differentiation, Dukes' stage, DNA ploidy and survival. Staining was predominantly cytoplasmic despite the suspected nuclear location of p62c-myc and there was considerable staining of fibroblasts. When staining was compared in frozen and paraffin-embedded sections fixed in different ways, different patterns were observed. Acetone-fixed frozen sections exhibited weak nuclear and cytoplasmic staining or were negative. In formol-saline fixed frozen sections, there was stronger predominantly nuclear staining. In paraffin-embedded sections staining was predominantly cytoplasmic. This study suggests that c-myc expression is enhanced in the majority of colorectal carcinomas and although independent of clinical behaviour, may be a common event in malignant transformation. However, since staining is affected by fixation and processing, data obtained using Myc 1-6E10 on routinely processed specimens should be interpreted with caution.Citation
A critical appraisal of the immunohistochemical detection of the c-myc oncogene product in colorectal cancer. 1987, 56 (6):779-83 Br. J. CancerJournal
British Journal of CancerPubMed ID
3325094Type
ArticleLanguage
enISSN
0007-0920Related articles
- Detection of the c-myc oncogene product in colonic polyps and carcinomas.
- Authors: Stewart J, Evan G, Watson J, Sikora K
- Issue date: 1986 Jan
- Distribution of cells expressing myc proteins in human colorectal epithelium, polyps, and malignant tumors.
- Authors: Melhem MF, Meisler AI, Finley GG, Bryce WH, Jones MO, Tribby II, Pipas JM, Koski RA
- Issue date: 1992 Nov 1
- Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
- Authors: Schwartz B, Benharroch D, Prinsloo I, Cagnano E, Lamprecht SA
- Issue date: 1995 Jan-Feb
- Detection of the c-myc oncogene product in testicular cancer.
- Authors: Sikora K, Evan G, Stewart J, Watson JV
- Issue date: 1985 Aug
- c-myc oncogene expression in colorectal cancer.
- Authors: Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson J
- Issue date: 1987 Apr 1
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)